Jynneos

Adult Dosing .

Dosage forms:  INJ

Special Note

[FDA emergency use authorization (EUA)]

Info: for active immunization by intradermal injection to prevent mpox dz in high-risk pts; avail. from Strategic National Stockpile, contact local health department

[mandatory reporting for EUA]

Info: vaccine administration errors, serious adverse events, myocarditis or pericarditis cases, and thromboembolic or neurovascular events following vaccination must be reported to Vaccine Adverse Event Reporting System (vaers.hhs.gov/reportevent.html or 1-800-822-7967) and Bavarian Nordic (1-844-4BAVARIAN)

smallpox dz prevention

[primary]

Dose: 0.5 mL SC x2 doses 4wk apart; Info: for high-risk pts, incl. immunocompromised pts

[booster, low-risk pts]

Dose: 0.5 mL SC q10y; Info: for individuals w/ ongoing occupational exposure to less virulent orthopoxviruses

[booster, high-risk pts]

Dose: 0.5 mL SC q2y; Info: for individuals w/ ongoing occupational exposure to more virulent orthopoxviruses

mpox dz prevention

[primary, SC route]

Dose: 0.5 mL SC x2 doses 4wk apart; Info: for high-risk pts, incl. immunocompromised pts

[primary, intradermal route]

Dose: 0.1 mL intradermally x2 doses 4wk apart; Info: for high-risk pts per FDA EUA

[booster, low-risk pts]

Dose: 0.5 mL SC q10y; Info: for individuals w/ ongoing occupational exposure to less virulent orthopoxviruses

[booster, high-risk pts]

Dose: 0.5 mL SC q2y; Info: for individuals w/ ongoing occupational exposure to more virulent orthopoxviruses

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Dosage forms:  INJ

Special Note

[FDA emergency use authorization (EUA)]

Info: for active immunization by subcutaneous injection to prevent mpox dz in high-risk pts; avail. from Strategic National Stockpile, contact local health department

[mandatory reporting for EUA]

Info: vaccine administration errors, serious adverse events, myocarditis or pericarditis cases, and thromboembolic or neurovascular events following vaccination must be reported to Vaccine Adverse Event Reporting System (vaers.hhs.gov/reportevent.html or 1-800-822-7967) and Bavarian Nordic (1-844-4BAVARIAN)

mpox dz prevention

[primary]

Dose: 0.5 mL SC x2 doses 4wk apart; Info: for high-risk pts per FDA EUA

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]